BPC-157 Research in 2026: What the Science Shows, What It Doesn’t, and How to Buy It Right

Roughly 200 published studies. One completed human trial — and even that one had its data pulled before anyone outside the sponsor got to review it. That gap is basically the whole BPC-157 story in a single sentence, and it’s exactly why so many researchers land on this page still not sure what to believe.

For laboratory and in-vitro research use only. BPC-157 is not a drug, has not been evaluated by the FDA for safety or efficacy, and is not sold or intended for human or veterinary use, administration, or consumption. Everything below is written for people designing or sourcing research — not for anyone looking for a how-to-use guide, because that guide doesn’t exist here.

If you’ve spent any time in a peptide research forum this year, you’ve watched BPC-157 dominate the conversation. It shows up in Reddit threads, in PubMed alerts, in every “top peptides to watch” roundup — and somewhere between the hype and the actual data, a lot of buyers lose the thread. So let’s fix that! Browse the full research peptides catalog while you’re here — but first: what does the research really say? Why does the FDA keep sending warning letters about it? And why do so many people end up burned by the vendor before the compound even matters?

Picture this: you order from a site with slick branding and a “99% pure” badge on every product photo. Three weeks later the vial shows up with a COA that’s either six months old, formatted like a template, or just… missing. Now your protocol is on hold and you’re emailing a supplier that may never write back. Ask around — nearly every lab that’s ordered peptides online for more than a year has a version of this story. It’s not really a BPC-157 problem. It’s a documentation problem, and it’s the reason this guide spends as much time on sourcing as it does on the science.

What Is BPC-157, Exactly?

BPC-157 — sometimes written BPC 157, and known in older papers as PL-14736 or Bepecin — is a synthetic pentadecapeptide, meaning it’s built from 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It’s modeled on a fragment identified in human gastric juice, which explains the name “Body Protection Compound.”

Here’s the part a lot of vendor pages skip: there are two forms in circulation, and they’re not interchangeable on paper. The free-base form carries CAS 137525-51-0. The acetate salt — the form most research suppliers actually stock — carries CAS 1628202-19-6, with a molecular formula of C62H98N16O22 and a molecular weight of roughly 1,419.5 g/mol. If a listing doesn’t say which one you’re getting, that’s your first red flag, not your last.

It isn’t an FDA-approved drug. It isn’t a dietary supplement. It sits in a research-chemical category by default, not by marketing choice — which is exactly why the paperwork around it matters as much as the vial itself.

What the Research Actually Shows

Let’s talk about who’s actually done this work, because it’s a smaller circle than the hype suggests. Roughly 200 PubMed-indexed studies on BPC-157 list either Predrag Sikiric or Sven Seiwerth — both at the University of Zagreb — as an author. That’s not a knock on the science — Croatian researchers have been remarkably productive (STAT News, February 2026)! But it does mean the evidence base is narrower and more concentrated than a “200 studies” headline implies, and any researcher building on this literature should know exactly whose lab it’s coming from.

The proposed mechanism: angiogenesis and growth factor activity

Preclinical work has focused heavily on BPC-157’s interaction with the nitric oxide system and VEGFR2-mediated angiogenesis pathways, alongside reported effects on growth factor expression, including EGF-related mRNA activity. These are cell- and animal-level mechanistic findings — the kind of data that explains why researchers keep investigating this compound, not evidence of what it does in a person.

Tissue and musculoskeletal models

Tendon, ligament, and cutaneous wound-healing studies make up a large share of the literature, with reported associations between compound exposure and cell migration, neovascularization, and outgrowth markers in animal tissue. A 2025 systematic review in orthopaedic sports medicine catalogued this body of work in detail — and also flagged, in plain language, that comparable controlled human data simply doesn’t exist yet.

Gastrointestinal research

This is arguably where the literature is deepest: models of alcohol-induced gastric injury, NSAID-induced ulceration, and carbon-tetrachloride-induced liver injury, where BPC-157 administration correlated with reduced tissue damage markers in treated animals. Some of the same body of work extends into intestinal anastomosis and fistula-repair models (Kleczkowska et al., Pharmaceuticals, 2025).

CNS and neurological models

Rodent studies have looked at serotonin- and dopamine-pathway activity, with a smaller set of papers examining neuroprotective effects against specific neurotoxins. None of this rises to clinical evidence — it’s mechanistic, animal-level signal that justifies more research, full stop.

The human data gap (and why it matters more than any of the above)

Here’s the honest part most vendor content buries: human-subject data on BPC-157 is genuinely thin. The one registered human trial — a 2015–2016 Phase I study under the name Bepecin, with 42 healthy volunteers — was discontinued, and its data was withdrawn from public registries before outside peer review. A small, more recent pilot study has since looked at intravenous administration safety, but it doesn’t change the bigger picture. If you’re designing a new protocol around this compound, you’re building on animal and in-vitro data, not human trials. Treat it that way.

Why BPC-157 Is Still “Research Use Only” — and Why That’s Not Vendor Legalese

This is the section every buyer should actually read before they check out anywhere. BPC-157 has not been approved by the FDA for any use. In 2023, the FDA placed it on its list of substances carrying “significant safety risks,” a determination that bars compounding pharmacies from using it. The World Anti-Doping Agency added it to its Prohibited List (category S0) back in 2022, and it also sits on the U.S. Department of Defense’s Prohibited Dietary Supplement Ingredients List .

Then, in September 2025, the FDA issued a wave of warning letters to peptide sellers — with BPC-157 vendors specifically named — for advertising that marketed “research use only” products in ways that showed clear intent for human use. The agency’s own language, stated plainly in its warning letters, is blunt: an RUO label doesn’t exempt a product from drug regulation if the surrounding marketing says otherwise. That’s not a technicality. It’s the difference between a compliant research supplier and one that’s one complaint away from a shutdown notice.

The Real Buying Problem: Purity, COAs, and Trust

Here’s a question worth sitting with for a second: if two vendors both sell “BPC-157, 99% purity,” and one of them can’t produce a batch-specific Certificate of Analysis on request, which one do you actually trust? Purity claims printed on a product page are marketing. A COA tied to the specific lot in your hand is data. Those are not the same thing, and treating them as interchangeable is how research budgets get wasted on compromised material.

What a real COA should show

At minimum: the batch or lot number matching your vial, HPLC-determined purity (reported, not asserted), mass spectrometry confirming molecular weight, and a testing date with an issuing lab attached. If a vendor hedges on any of that before you’ve paid, that tells you everything.

How NexaPeptideLabs verifies every batch

NexaPeptideLabs orders BPC-157 in defined production batches and requires independent third-party HPLC and mass spectrometry verification before any batch is released for sale, consistent with our Certificate of Analysis and lab-testing standards. Each COA is tied to its specific lot — not pooled across runs — and it’s available at checkout, not locked behind a support ticket. If you’re ready to source BPC-157 for an actual protocol, the BPC-157 research peptide page has the current batch documentation posted, and it’s worth five minutes of your time before you buy anywhere else. Every order is subject to our research-use policy, so know that going in.

How to Store BPC-157 for Laboratory Use

Lyophilized BPC-157 should be kept at −20°C, sealed, and protected from light and moisture. Once a vial is opened or reconstituted for lab assay purposes, minimize freeze-thaw cycles, aliquot what you need, and store aliquots at the temperature specified on that batch’s COA — stability data is lot-dependent, so don’t assume last quarter’s batch behaves identically to this one. Frost-free freezers with fluctuating internal temperatures are worse for peptide integrity than a standard chest freezer held at a steady −20°C, even though they look more convenient.

Demand for research-grade peptides has grown fast enough that sourcing infrastructure hasn’t fully caught up — the global peptide therapeutics market was valued at roughly $140.9 billion in 2025 and is projected to reach $294.6 billion by 2033. Labs from the United States to Canada, Germany, and France are all chasing the same characterized material, which is exactly why COA discipline matters more this year than it did five years ago, not less. (Buyers outside the U.S. are responsible for checking their own country’s import and research-chemical regulations before ordering.)

FAQs About BPC-157

What is BPC-157?

It’s a synthetic pentadecapeptide — a 15-amino-acid research compound modeled on a fragment identified in human gastric juice, studied in preclinical models for tissue, gastrointestinal, and mechanistic research applications.

What is BPC-157 used for in research?

Published preclinical literature has investigated it in animal and in-vitro models related to gastrointestinal protection, tendon and wound-tissue repair, and CNS/neurochemical activity. These are research findings, not evidence of effects in humans.

Is BPC-157 legal to buy?

It can currently be purchased as a research chemical in the U.S. when sold and used strictly for laboratory/in-vitro purposes. It’s not an approved drug or supplement, and the FDA has taken enforcement action against sellers whose marketing implies human use despite RUO labeling.

Is BPC-157 FDA approved?

No. It has not completed FDA review for any indication, and the FDA has explicitly flagged it as carrying unresolved safety questions.

What’s the difference between BPC-157 and TB-500?

Both are research peptides studied in tissue-repair contexts, but they’re structurally unrelated: BPC-157 is a 15-amino-acid gastric-derived pentadecapeptide, while TB-500 is a synthetic fragment of thymosin beta-4. Researchers sometimes study them in parallel to compare proposed mechanisms.

Does BPC-157 show up on any banned-substance lists?

Yes. It’s on the World Anti-Doping Agency’s Prohibited List (added 2022, category S0) and the U.S. Department of Defense’s Prohibited Dietary Supplement Ingredients List.

What does a Certificate of Analysis (COA) actually show?

A COA documents a specific batch’s identity and purity — typically HPLC purity analysis plus mass spectrometry confirming molecular weight — tied to that lot’s number and test date.

How should BPC-157 be stored?

At −20°C, sealed, protected from light and moisture. Reconstituted material should be aliquoted and stored per the specific batch’s technical data sheet to limit freeze-thaw degradation.

What’s the CAS number for BPC-157?

The free-base form is CAS 137525-51-0. The acetate salt commonly sold for research is CAS 1628202-19-6.

Why do all BPC-157 listings say “research use only”?

Because that’s its actual regulatory status — it’s not an approved drug, and the FDA has stated plainly that RUO labeling doesn’t exempt a product from drug regulation if a seller’s marketing suggests otherwise.

Has BPC-157 been tested in human clinical trials?

Only one was ever registered — a 2015–2016 Phase I study with 42 healthy volunteers — and it was discontinued, with its data withdrawn before external peer review. A small recent pilot safety study exists, but the evidence base remains preclinical overall.

Where can I buy BPC-157 with a verified COA?

NexaPeptideLabs posts batch-specific, third-party-verified COAs at checkout on its BPC-157 product listing  worth comparing against any vendor that won’t show you a COA before you pay.